Clinical Validation of the Somatic FANCD2 Mutation (c.2022-5C>T) as a Novel Molecular Biomarker for Early Disease Progression in Chronic Myeloid Leukemia: A Case–Control Study. The gene discussed is FANCD2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.